{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-060239","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.423503+00:00","generated_at":"2026-06-15T01:38:45.026987+00:00","sec_items":["2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nuvectis Pharma gets FDA clearance to begin Phase 1 trial for NXP900","bullets":["FDA cleared IND for NXP900, including Phase 1 clinical trial protocol.","NXP900 is a precision oncology drug; Nuvectis now has two clinical-stage candidates.","CEO Ron Bentsur: IND clearance is a significant milestone for corporate strategy.","NXP900 targets cancers with unmet medical need via differentiated mechanism of action."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-060239","json":"https://secwatch.observer/filing/0001104659-23-060239.json","markdown":"https://secwatch.observer/filing/0001104659-23-060239.md","text":"https://secwatch.observer/filing/0001104659-23-060239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923060239/0001104659-23-060239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465923060239/tm2315778d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:38:45.026987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}